Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00292188
Other study ID # A0081064
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date January 2006
Est. completion date May 2008

Study information

Verified date April 2011
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the efficacy of pregabalin compared to placebo in the treatment of posttraumatic peripheral neuropathic pain


Recruitment information / eligibility

Status Completed
Enrollment 255
Est. completion date May 2008
Est. primary completion date May 2008
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Diagnosis of Posttraumatic Peripheral Neuropathic Pain (NeP) syndrome, including post-surgical NeP, NeP due to peripheral nerve injury, and phantom limb pain, confirmed by a qualified pain specialist and persisting for a minimum of 3 months following the traumatic event Exclusion Criteria: - Subjects whose posttraumatic neuropathic pain is due to Complex Regional Pain Syndrome (CRPS, Type I or Type II) - NeP not due to trauma, and not peripheral pain

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
pregabalin
pregabalin
Placebo
placebo

Locations

Country Name City State
Belgium Pfizer Investigational Site Brussels
Belgium Pfizer Investigational Site Genk
Belgium Pfizer Investigational Site Liege
Belgium Pfizer Investigational Site Liège
Belgium Pfizer Investigational Site Pellenberg
Belgium Pfizer Investigational Site Wilrijk
Canada Pfizer Investigational Site Calgary Alberta
Canada Pfizer Investigational Site Sarnia Ontario
Canada Pfizer Investigational Site Toronto Ontario
Canada Pfizer Investigational Site Vancouver British Columbia
Denmark Pfizer Investigational Site Aarhus C
Denmark Pfizer Investigational Site Hvidovre
Finland Pfizer Investigational Site HUS
Finland Pfizer Investigational Site Tampere
Italy Pfizer Investigational Site Milano
Italy Pfizer Investigational Site Montescano (PV)
Italy Pfizer Investigational Site Roma
Netherlands Pfizer Investigational Site Alkmaar
Netherlands Pfizer Investigational Site Amsterdam NH
Netherlands Pfizer Investigational Site Breda
Netherlands Pfizer Investigational Site Kampen
Netherlands Pfizer Investigational Site Roosendaal
Netherlands Pfizer Investigational Site Tilburg NB
Portugal Pfizer Investigational Site Almada
Portugal Pfizer Investigational Site Amadora
Portugal Pfizer Investigational Site Coimbra
Portugal Pfizer Investigational Site Funchal
Portugal Pfizer Investigational Site Guimarães
Portugal Pfizer Investigational Site Lisboa
Portugal Pfizer Investigational Site Lisboa
Portugal Pfizer Investigational Site Porto
Romania Pfizer Investigational Site Bucharest
Romania Pfizer Investigational Site Bucuresti
Romania Pfizer Investigational Site Bucuresti
Romania Pfizer Investigational Site Iasi
Sweden Pfizer Investigational Site Linkoping
Sweden Pfizer Investigational Site Lund
Sweden Pfizer Investigational Site Stockholm
Switzerland Pfizer Investigational Site Bern
Switzerland Pfizer Investigational Site Geneve 14
United Kingdom Pfizer Investigational Site Birmingham
United Kingdom Pfizer Investigational Site Glasgow
United Kingdom Pfizer Investigational Site Leeds
United Kingdom Pfizer Investigational Site Plymouth

Sponsors (1)

Lead Sponsor Collaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Countries where clinical trial is conducted

Belgium,  Canada,  Denmark,  Finland,  Italy,  Netherlands,  Portugal,  Romania,  Sweden,  Switzerland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Weekly Mean Pain Score at End of Treatment (Week 8) From Daily Pain Diary Daily Pain Diary scale : mean score from 11-point numerical scale of pain; range: 0 (no pain) to 10 (worst possible pain). Endpoint weekly mean pain score: mean of the last 7 available pain scores from a daily pain diary during double blind treatment. each day of Week 8
Secondary Hospital Anxiety and Depression Scale (HADS) Anxiety Score Hospital Anxiety and Depression Scale Anxiety Score (HADS-A) consists of 7 items that are assessed by a score of 0 = no anxiety to 3 = severe feeling of anxiety. The anxiety subscale determines a state of generalized anxiety (including anxious mood, restlessness, anxious thoughts, panic attacks). Score range = 0 to 21; higher scores indicate a greater intensity of anxiety Week 8
Secondary Hospital Anxiety and Depression Scale (HADS) Depression Score Hospital Anxiety and Depression Scale Depression Score (HADS-D) consists of 7 items that are assessed by a score of 0 = no depression to 3 = severe feeling of depression. The depression subscale focuses on the state of lost interest and diminished pleasure response ("lowering of hedonic tone"). Score range = 0 to 21; higher scores indicate a greater intensity of depression Week 8
Secondary Hospital Anxiety and Depression Scale (HADS) Anxiety Score - FAS Subset With Moderate/Severe Baseline Scores Hospital Anxiety and Depression Scale Anxiety Score (HADS-A) consists of 7 items that are assessed by a score of 0 = no anxiety to 3 = severe feeling of anxiety. The anxiety subscale determines a state of generalized anxiety (including anxious mood, restlessness, anxious thoughts, panic attacks). Score range = 0 to 21; higher scores indicate a greater intensity of anxiety. Week 8
Secondary Hospital Anxiety and Depression Scale (HADS) Depression Score - FAS Subset With Moderate/Severe Baseline Scores Hospital Anxiety and Depression Scale (HADS-D) consists of 7 items that are assessed by a score of 0 = no depression to 3 = severe feeling of depression. The depression subscale focuses on the state of lost interest and diminished pleasure response (lowering of hedonic tone). Score range = 0 to 21; higher scores indicate a greater intensity of depression Week 8
Secondary Weekly Mean Pain Score From Daily Pain Diary Daily Pain Diary scale : mean score from 11-point numerical scale of pain; range:0 (no pain) to 10 (worst possible pain). Mean of scores available for each week. Baseline through Week 8
Secondary Number of Subjects With 30% and 50% Response in Weekly Mean Daily Pain Rating Score (DPRS) From Baseline Until Endpoint (Week 8) Based on weekly mean daily pain rating score (DPRS), responders were defined as subjects with a >= 30% and >=50% reduction in weekly mean scores from baseline until endpoint (Week 8). Endpoint was calculated as the mean of the last 7 available pain scores from the daily pain diary while in the double-blind treatment phase. Baseline, Week 8
Secondary Weekly Mean Sleep Interference Score 11-point numerical scale with which the patient describes pain interference with sleep over past 24 hours; range: 0 (pain does not interfere with sleep) to 10 (pain completely interferes with sleep). Endpoint weekly mean score: mean of last 7 available scores from daily sleep interference diary during double-blind treatment. Week 8
Secondary Medical Outcome Study (MOS) Sleep Subscales Medical Outcome Study (MOS) is a patient-rated questionnaire consisting of 12 items that assess key constructs of sleep (7 subscales as well as a 9-item overall sleep problems index. MOS-Sleep Scale is scored from 0 to 100. A higher score indicates more disturbance. Week 8
Secondary Medical Outcome Study (MOS) Optimal Sleep Number of subjects responding to have had optimal sleep. Optimal sleep is 1 item in the Medical Outcome Study (MOS)sleep scale, a patient-reported measure consisting of twelve items that assess the key constructs of sleep. Subjects were asked to recall sleep-related activities over the past week. Week 8
Secondary Patient Global Impression of Change (PGIC) Patient Global Impression of Change (PGIC): a patient-rated instrument that measures change in patient's overall status on a 7-point scale; range: 1 Very Much Improved to 7 Very Much Worse. Week 8
Secondary Clinical Global Impression of Change (CGIC) Clinical Global Impression of Change (CGIC): clinician's judgment of overall change in the patient's condition over a defined period on a 7-point scale; range: 1 Very Much Improved to 7 Very Much Worse. Week 8
Secondary Pain Treatment Satisfaction Scale (PTSS): Impact of Current Pain Medication Pain Treatment Satisfaction Scale (PTSS); Impact of Current Pain Medication: measure of patient satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment. Screening, Week 8
Secondary Pain Treatment Satisfaction Scale (PTSS): Satisfaction With Current Pain Medication Pain Treatment Satisfaction Scale (PTSS); Satisfaction with Current Pain Medication: measure of patient satisfaction with treatment for acute or chronic pain. Response range:1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment. Screening, Week 8
Secondary Pain Treatment Satisfaction Scale (PTSS): Medication Characteristics Pain Treatment Satisfaction Scale (PTSS); Medication Characteristics: measure of patient satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment. Screening, Week 8
Secondary Pain Treatment Satisfaction Scale (PTSS): Efficacy Pain Treatment Satisfaction Scale (PTSS); Efficacy: measure of patient satisfaction with treatment for acute or chronic pain. Response range: 1 (strongly agree) to 5 (strongly disagree). Mean scores were calculated and transformed onto a scale of 0-100, range: 0 = worst possible satisfaction to 100 = best possible satisfaction with pain treatment. Screening, Week 8
Secondary Modified Brief Pain Inventory Short Form (m-BPI-sf) Modified Brief Pain Inventory Short Form (m-BPI-sf): self-administered questionnaire to assess severity of pain (measured by 4 items)and impact of pain on daily functions (measured by 7 items)in past 24 hours. Items are rated on an 11-point scale ranging from 0 to 10, with higher scores indicating greater pain and/or interference due to pain. Baseline, Week 8
Secondary Neuropathic Pain Symptom Inventory (NPSI) Total Intensity Score Neuropathic Pain Symptom Inventory (NPSI) includes 10 descriptors (scale 0-10) of different pain symptoms & 2 temporal items assessing the duration of spontaneous ongoing and paroxysmal pain. A total intensity score is calculated by sub grouping the questions into five pain dimensions, summing the five sub groups, and converting into a percentage. Week 8
Secondary Medical Outcome Study Cognitive Subscale (MOS-Cog); Reasoning The number of subjects' responses to each of the 6 questions on the Medical Outcome Study Cognitive (MOS-Cog) subscale were summarized at baseline and Week 8. Category range: all of the time to none of the time. No formal statistical modeling was used. Baseline, Week 8
Secondary Medical Outcome Study Cognitive Subscale (MOS-Cog); Concentration The number of subjects' responses to each of the 6 questions on the Medical Outcome Study Cognitive (MOS-Cog) subscale were summarized at baseline and Week 8. Category range: all of the time to none of the time. No formal statistical modeling was used. Baseline, Week 8
Secondary Medical Outcome Study Cognitive Subscale (MOS-Cog); Confusion The number of subjects' responses to each of the 6 questions on the Medical Outcome Study Cognitive (MOS-Cog) subscale were summarized at baseline and Week 8. Category range: all of the time to none of the time. No formal statistical modeling was used. Baseline, Week 8
Secondary Medical Outcome Study Cognitive Subscale (MOS-Cog); Memory The number of subjects' responses to each of the 6 questions on the Medical Outcome Study Cognitive (MOS-Cog) subscale were summarized at baseline and Week 8. Category range: all of the time to none of the time. No formal statistical modeling was used. Baseline, Week 8
Secondary Medical Outcome Study Cognitive Subscale (MOS-Cog); Attention The number of subjects' responses to each of the 6 questions on the Medical Outcome Study Cognitive (MOS-Cog) subscale were summarized at baseline and Week 8. Category range: all of the time to none of the time. No formal statistical modeling was used. Baseline, Week 8
Secondary Medical Outcome Study Cognitive Subscale (MOS-Cog); Thinking The number of subjects' responses to each of the 6 questions on the Medical Outcome Study Cognitive (MOS-Cog) subscale were summarized at baseline and Week 8. Category range: all of the time to none of the time. No formal statistical modeling was used. Baseline, Week 8
Secondary Davidson Trauma Scale (DTS): Severity Self-rated instrument to measure symptom severity and treatment outcome in post traumatic stress disorder (PTSD). Scale of 17 PTSD symptoms over previous week; frequency scale: 0 (not at all) to 4 (every day), and severity 0 (not at all distressing) to 4(extremely distressing). The total Davidson Trauma Scale score ranges from 0 to 136. Baseline, Week 8
Secondary Davidson Trauma Scale (DTS): Frequency Self-rated instrument to measure symptom severity and treatment outcome in post traumatic stress disorder (PTSD). Scale of 17 PTSD symptoms over previous week; frequency scale: 0 (not at all) to 4 (every day), and severity 0 (not at all distressing) to 4(extremely distressing). The total Davidson Trauma Scale score ranges from 0 to 136. Baseline, Week 8
Secondary Davidson Trauma Scale (DTS): Total Score Self-rated instrument to measure symptom severity and treatment outcome in post traumatic stress disorder (PTSD). Scale of 17 PTSD symptoms over previous week; frequency scale: 0 (not at all) to 4 (every day), and severity 0 (not at all distressing) to 4(extremely distressing). The total Davidson Trauma Scale score ranges from 0 to 136. Baseline, Week 8
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04066933 - Forms of Cervical Brachial Syndrome Treated With Plasma Concentrate Enriched for A2M
Completed NCT01202227 - An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain Phase 3
Completed NCT00922987 - Clinical Study With Lyrica In Patients Suffering From Epilepsy
Terminated NCT00964990 - A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia) Phase 2
Recruiting NCT00740571 - Amitriptyline or Pregabalin to Treat Neuropathic Pain in Incurable Cancer Phase 3
Terminated NCT02747758 - Transcranial Direct Current Stimulation (tDCS) in Chronic Neuropathy N/A
Completed NCT05464199 - Home-based EEG Neurofeedback for Chronic Neuropathic Pain Phase 1
Completed NCT02490436 - Novel Treatment Option for Neuropathic Pain Phase 2
Completed NCT01974791 - GET Living: Graded Exposure Treatment for Children and Adolescents With Chronic Pain N/A
Completed NCT01279018 - Persistent Pain After Breast Cancer Treatment With Docetaxel N/A
Not yet recruiting NCT00944502 - To Evaluate the Efficacy and Tolerability of the Use of Vitatonus Dexa Compared to Dexamethasone in Patients With Neuralgia of Various Origins Phase 3
Completed NCT02957851 - EMONO for the Treatment of Peripheral Neuropathic Pain Phase 2
Completed NCT02180880 - Symptom Based Treatment of Neuropathic Pain Phase 4
Active, not recruiting NCT01508676 - Effects of Pennsaid on Clinical Neuropathic Pain N/A
Completed NCT00631943 - A Study to Evaluate the Efficacy and Safety of Pregabalin (Lyrica) for the Treatment of Nerve Pain Phase 3
Completed NCT03973983 - Comparison of Ultrasound-guided Transgluteal and Finger-guided Transvaginal Pudendal Nerve Block Techniques N/A
Terminated NCT03296111 - Patients With Ocular Neuropathic Pain: Description of Pain and Impact on Their Quality of Life
Not yet recruiting NCT06398847 - Virtual Reality (VR) Self-Hypnosis Software N/A
Terminated NCT02460107 - Botulinum Toxin Type A for Neuropathic Pain in Patients With Diabetic Peripheral Polyneuropathy Early Phase 1
Recruiting NCT01788410 - MRI-Guided Cryoablation to Alleviate Pain in Head, Neck and Spine